|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KHSRP |
Gene summary for KHSRP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KHSRP | Gene ID | 8570 |
| Gene name | KH-type splicing regulatory protein | |
| Gene Alias | FBP2 | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q92945 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8570 | KHSRP | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.13e-06 | 3.08e-01 | 0.0155 |
| 8570 | KHSRP | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.97e-06 | 4.53e-01 | -0.1808 |
| 8570 | KHSRP | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.88e-08 | 5.27e-01 | -0.0811 |
| 8570 | KHSRP | HTA11_78_2000001011 | Human | Colorectum | AD | 1.05e-09 | 4.74e-01 | -0.1088 |
| 8570 | KHSRP | HTA11_347_2000001011 | Human | Colorectum | AD | 2.21e-23 | 6.52e-01 | -0.1954 |
| 8570 | KHSRP | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.53e-04 | 3.92e-01 | -0.1207 |
| 8570 | KHSRP | HTA11_83_2000001011 | Human | Colorectum | SER | 1.09e-05 | 4.38e-01 | -0.1526 |
| 8570 | KHSRP | HTA11_696_2000001011 | Human | Colorectum | AD | 1.81e-12 | 4.64e-01 | -0.1464 |
| 8570 | KHSRP | HTA11_866_2000001011 | Human | Colorectum | AD | 2.67e-14 | 4.67e-01 | -0.1001 |
| 8570 | KHSRP | HTA11_1391_2000001011 | Human | Colorectum | AD | 6.74e-24 | 9.55e-01 | -0.059 |
| 8570 | KHSRP | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.68e-09 | 6.60e-01 | -0.1706 |
| 8570 | KHSRP | HTA11_546_2000001011 | Human | Colorectum | AD | 1.02e-08 | 5.38e-01 | -0.0842 |
| 8570 | KHSRP | HTA11_866_3004761011 | Human | Colorectum | AD | 1.03e-14 | 5.49e-01 | 0.096 |
| 8570 | KHSRP | HTA11_4255_2000001011 | Human | Colorectum | SER | 9.14e-05 | 6.86e-01 | 0.0446 |
| 8570 | KHSRP | HTA11_7663_2000001011 | Human | Colorectum | SER | 5.34e-07 | 6.81e-01 | 0.0131 |
| 8570 | KHSRP | HTA11_10623_2000001011 | Human | Colorectum | AD | 1.86e-04 | 5.04e-01 | -0.0177 |
| 8570 | KHSRP | HTA11_10711_2000001011 | Human | Colorectum | AD | 5.80e-05 | 4.36e-01 | 0.0338 |
| 8570 | KHSRP | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.23e-49 | 1.15e+00 | 0.0674 |
| 8570 | KHSRP | HTA11_6818_2000001011 | Human | Colorectum | AD | 3.95e-04 | 5.27e-01 | 0.0112 |
| 8570 | KHSRP | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.13e-07 | 4.78e-01 | 0.0588 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0015931110 | Thyroid | PTC | nucleobase-containing compound transport | 120/5968 | 222/18723 | 5.45e-12 | 2.35e-10 | 120 |
| GO:0043487111 | Thyroid | PTC | regulation of RNA stability | 97/5968 | 170/18723 | 9.51e-12 | 3.97e-10 | 97 |
| GO:005102817 | Thyroid | PTC | mRNA transport | 78/5968 | 130/18723 | 3.44e-11 | 1.26e-09 | 78 |
| GO:0061013111 | Thyroid | PTC | regulation of mRNA catabolic process | 94/5968 | 166/18723 | 3.55e-11 | 1.29e-09 | 94 |
| GO:0043488111 | Thyroid | PTC | regulation of mRNA stability | 90/5968 | 158/18723 | 5.98e-11 | 2.11e-09 | 90 |
| GO:006115719 | Thyroid | PTC | mRNA destabilization | 52/5968 | 84/18723 | 1.40e-08 | 3.30e-07 | 52 |
| GO:006101419 | Thyroid | PTC | positive regulation of mRNA catabolic process | 53/5968 | 87/18723 | 2.25e-08 | 5.16e-07 | 53 |
| GO:005077919 | Thyroid | PTC | RNA destabilization | 53/5968 | 88/18723 | 3.91e-08 | 8.51e-07 | 53 |
| GO:003424916 | Thyroid | PTC | negative regulation of cellular amide metabolic process | 122/5968 | 273/18723 | 5.50e-06 | 6.64e-05 | 122 |
| GO:001714815 | Thyroid | PTC | negative regulation of translation | 108/5968 | 245/18723 | 3.75e-05 | 3.48e-04 | 108 |
| GO:00105868 | Thyroid | PTC | miRNA metabolic process | 19/5968 | 27/18723 | 4.57e-05 | 4.11e-04 | 19 |
| GO:200105718 | Thyroid | PTC | reactive nitrogen species metabolic process | 38/5968 | 82/18723 | 4.25e-03 | 2.02e-02 | 38 |
| GO:004620919 | Thyroid | PTC | nitric oxide metabolic process | 37/5968 | 81/18723 | 6.35e-03 | 2.79e-02 | 37 |
| GO:000680919 | Thyroid | PTC | nitric oxide biosynthetic process | 35/5968 | 76/18723 | 6.68e-03 | 2.89e-02 | 35 |
| GO:008016419 | Thyroid | PTC | regulation of nitric oxide metabolic process | 30/5968 | 64/18723 | 8.53e-03 | 3.58e-02 | 30 |
| GO:004542819 | Thyroid | PTC | regulation of nitric oxide biosynthetic process | 29/5968 | 62/18723 | 9.96e-03 | 4.07e-02 | 29 |
| GO:000838034 | Thyroid | ATC | RNA splicing | 270/6293 | 434/18723 | 7.50e-35 | 1.19e-31 | 270 |
| GO:0009896210 | Thyroid | ATC | positive regulation of catabolic process | 290/6293 | 492/18723 | 2.15e-31 | 1.94e-28 | 290 |
| GO:0031331210 | Thyroid | ATC | positive regulation of cellular catabolic process | 258/6293 | 427/18723 | 2.09e-30 | 1.65e-27 | 258 |
| GO:000037534 | Thyroid | ATC | RNA splicing, via transesterification reactions | 200/6293 | 324/18723 | 1.75e-25 | 7.39e-23 | 200 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KHSRP | SNV | Missense_Mutation | c.315T>G | p.Phe105Leu | p.F105L | Q92945 | protein_coding | tolerated(0.07) | benign(0.015) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| KHSRP | SNV | Missense_Mutation | c.1496N>C | p.Leu499Pro | p.L499P | Q92945 | protein_coding | deleterious(0.04) | possibly_damaging(0.897) | TCGA-B6-A0X5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| KHSRP | SNV | Missense_Mutation | novel | c.646N>T | p.Arg216Cys | p.R216C | Q92945 | protein_coding | deleterious(0) | possibly_damaging(0.836) | TCGA-D8-A1JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | ChemotherapyHormone Therapy | doxorubicine | SD |
| KHSRP | SNV | Missense_Mutation | novel | c.1447N>A | p.Gln483Lys | p.Q483K | Q92945 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KHSRP | insertion | Frame_Shift_Ins | novel | c.1608_1609insG | p.Pro537AlafsTer25 | p.P537Afs*25 | Q92945 | protein_coding | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| KHSRP | SNV | Missense_Mutation | c.1047N>C | p.Gln349His | p.Q349H | Q92945 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| KHSRP | SNV | Missense_Mutation | novel | c.956C>G | p.Ser319Cys | p.S319C | Q92945 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| KHSRP | SNV | Missense_Mutation | c.1051N>C | p.Asp351His | p.D351H | Q92945 | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| KHSRP | SNV | Missense_Mutation | novel | c.527N>T | p.Cys176Phe | p.C176F | Q92945 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-VS-A8EI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| KHSRP | SNV | Missense_Mutation | c.2027N>T | p.Ala676Val | p.A676V | Q92945 | protein_coding | tolerated(0.09) | probably_damaging(0.994) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8570 | KHSRP | NA | GO-Y030 | CHEMBL598509 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |